# A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

> **NCT05477849** · PHASE1 · RECRUITING · sponsor: **Shanghai Virogin Biotech Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

## Key facts

- **NCT ID:** NCT05477849
- **Lead sponsor:** Shanghai Virogin Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-23
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477849, "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05477849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*